SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAMPO, Gianluca Calogero
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.835
AS - Asia 20.048
EU - Europa 13.859
SA - Sud America 3.572
AF - Africa 500
OC - Oceania 69
Continente sconosciuto - Info sul continente non disponibili 14
AN - Antartide 1
Totale 68.898
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.983
SG - Singapore 8.065
FI - Finlandia 4.767
CN - Cina 4.364
BR - Brasile 2.783
VN - Vietnam 2.313
IT - Italia 2.178
DE - Germania 1.979
HK - Hong Kong 1.683
GB - Regno Unito 951
FR - Francia 762
UA - Ucraina 731
TR - Turchia 643
JP - Giappone 624
IN - India 528
PL - Polonia 497
RU - Federazione Russa 451
ID - Indonesia 406
SE - Svezia 375
CA - Canada 374
MX - Messico 359
BD - Bangladesh 312
NL - Olanda 270
AR - Argentina 268
ZA - Sudafrica 188
IQ - Iraq 182
ES - Italia 179
CO - Colombia 133
PK - Pakistan 131
AT - Austria 130
EC - Ecuador 126
BE - Belgio 98
UZ - Uzbekistan 78
LT - Lituania 77
VE - Venezuela 77
SA - Arabia Saudita 76
PH - Filippine 74
MY - Malesia 67
KR - Corea 66
AU - Australia 63
IE - Irlanda 60
MA - Marocco 58
CH - Svizzera 53
CZ - Repubblica Ceca 53
CL - Cile 50
EG - Egitto 48
AE - Emirati Arabi Uniti 46
PY - Paraguay 44
TN - Tunisia 43
JO - Giordania 41
KE - Kenya 40
PE - Perù 38
NP - Nepal 37
IR - Iran 33
AL - Albania 32
UY - Uruguay 32
TH - Thailandia 29
DZ - Algeria 26
JM - Giamaica 25
LB - Libano 24
KZ - Kazakistan 23
IL - Israele 21
PT - Portogallo 21
TW - Taiwan 21
AZ - Azerbaigian 20
DK - Danimarca 20
DO - Repubblica Dominicana 20
KG - Kirghizistan 20
OM - Oman 19
SN - Senegal 19
ET - Etiopia 18
HR - Croazia 18
RO - Romania 17
PS - Palestinian Territory 16
RS - Serbia 15
CR - Costa Rica 14
PA - Panama 14
BG - Bulgaria 13
CY - Cipro 13
SI - Slovenia 13
HU - Ungheria 12
GE - Georgia 11
NI - Nicaragua 11
BO - Bolivia 10
BH - Bahrain 9
GR - Grecia 9
LV - Lettonia 9
MD - Moldavia 9
SK - Slovacchia (Repubblica Slovacca) 9
SY - Repubblica araba siriana 9
CI - Costa d'Avorio 8
HN - Honduras 8
NO - Norvegia 8
XK - ???statistics.table.value.countryCode.XK??? 8
BY - Bielorussia 7
GY - Guiana 7
KW - Kuwait 7
QA - Qatar 7
TT - Trinidad e Tobago 7
EE - Estonia 6
Totale 68.749
Salva come PNG Salva come JPEG
Città #
Singapore 4.911
Ashburn 4.509
Helsinki 4.366
San Jose 2.512
Fairfield 2.306
Woodbridge 1.818
Hong Kong 1.640
Santa Clara 1.444
Beijing 1.360
Dallas 1.340
Houston 1.237
Chandler 1.034
Munich 1.029
Seattle 981
Wilmington 853
Ann Arbor 810
Cambridge 767
Jacksonville 765
Ho Chi Minh City 762
Los Angeles 655
New York 652
Tokyo 591
Hanoi 515
Warsaw 468
Council Bluffs 415
Lauterbourg 413
Ferrara 367
Izmir 344
Princeton 326
São Paulo 311
Jakarta 296
Shanghai 284
Nanjing 271
Milan 257
San Diego 213
Orem 211
London 207
Mexico City 206
Chicago 192
Turku 187
Frankfurt am Main 158
Bologna 151
Boardman 145
Montreal 135
Buffalo 134
Chennai 131
Brooklyn 123
Denver 122
Hefei 121
Nuremberg 115
Atlanta 113
Rio de Janeiro 109
Da Nang 104
Amsterdam 102
Haiphong 102
Toronto 102
Rome 99
Phoenix 96
Stockholm 96
Brussels 95
Johannesburg 94
Moscow 94
Boston 93
San Francisco 90
Tianjin 87
Poplar 81
Bremen 80
Manchester 80
Shenyang 78
The Dalles 78
Falkenstein 73
Mumbai 72
Nanchang 72
Tashkent 69
Washington 68
Baghdad 64
Lappeenranta 64
Redwood City 64
Falls Church 63
Ankara 58
Jiaxing 55
Salt Lake City 55
Belo Horizonte 54
Guangzhou 54
Paris 54
Columbus 52
Dhaka 52
Dublin 52
Quito 50
Biên Hòa 48
Changsha 47
Medellín 47
Mountain View 44
Brasília 43
New Delhi 43
Shenzhen 43
Vienna 42
Hebei 40
Hải Dương 40
Amman 39
Totale 46.654
Salva come PNG Salva come JPEG
Nome #
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 2.855
A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients 2.050
Applied coronary physiology for planning and guidance of percutaneous coronary interventions. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology 422
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial 416
Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation 379
Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): Rationale and design of a randomized clinical trial 367
Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: Systematic review and meta-analysis of randomized clinical trials 365
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease 356
Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury 333
Exercise Intervention to Improve Functional Capacity in Older Adults After Acute Coronary Syndrome 323
Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction 314
Diagnostic accuracy of baseline troponin and troponin change for the diagnosis of myocardial infarction complicated with heart failure 301
Atrial Longitudinal Strain Predicts New-Onset Atrial Fibrillation: A Systematic Review and Meta-Analysis 296
Evolving Routine Standards in Invasive Hemodynamic Assessment of Coronary Stenosis: The Nationwide Italian SICI-GISE Cross-Sectional ERIS Study 283
Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study) 277
Prospective identification of stent fracture by enhanced stent visualization system during percutaneous coronary intervention 277
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 275
Poor response to clopidogrel: current and future options for its management 275
How the functional assessment of culprit and non-culprit lesions may improve stratification and treatment of STEMI patients 263
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 260
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis 259
Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis 258
Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study 255
Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients with ST-Segment-Elevation Myocardial Infarction and Multivessel Disease 249
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 246
Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial 246
Characterization of Dermal Stem Cells of Diabetic Patients 246
The use of nutraceuticals to counteract atherosclerosis: The role of the Notch pathway 245
Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review 244
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials 242
High-dose BoluS TiRofibAn and Sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients 241
The assessment of scales of frailty and physical performance improves prediction of major adverse cardiac events in older adults with acute coronary syndrome 238
Tissue factor and coagulation factor VII levels during acute myocardial infarction: Association with genotype and adverse events 237
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study 237
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 235
Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention 232
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 231
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI 228
C subunit of F1/FO-ATP synthase as target for preventing the detrimental effect of myocardial ischemia/reperfusion injury 228
Mechanistic role of mPTP in ischemia-reperfusion injury 227
Reperfusion Damage - A Story of Success, Failure, and Hope 225
Grip strength predicts cardiac adverse events in patients with cardiac disorders: An individual patient pooled meta-analysis 224
SERPINA1 Gene Promoter Is Differentially Methylated in Peripheral Blood Mononuclear Cells of Pregnant Women 224
The Mitochondrial Permeability Transition Pore 222
Adenosine-Free Indexes vs. Fractional Flow Reserve for Functional Assessment of Coronary Stenoses: Systematic Review and Meta-Analysis 218
Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study 218
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 217
Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients 216
A serum proteome signature to predict mortality in severe COVID-19 patients 214
Nutritional status and all-cause mortality in older adults with acute coronary syndrome 213
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 212
BRS implantation in long lesions requiring device overlapping: Myth or reality? 212
Can we improve myocardial protection during ischaemic injury? 211
Context-dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress 210
Diagnostic performance of in-procedure angiography-derived quantitative flow reserve compared to pressure-derived fractional flow reserve: The FAVOR II Europe-Japan study 210
Contrast Associated Acute Kidney Injury and Mortality in Older Adults with Acute Coronary Syndrome: A Pooled Analysis of the FRASER and HULK Studies 210
Direct oral anticoagulants for the treatment of left ventricular thrombosis: an updated systematic review and meta-analysis 209
Angio-based index of microcirculatory resistance for the assessment of the coronary resistance: A proof of concept study 207
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial 204
Effectiveness of a novel nutraceutical compound containing red yeast rice, polymethoxyflavones and antioxidants in the modulation of cholesterol levels in subjects with hypercholesterolemia and low-moderate cardiovascular risk: The NIRVANA study 204
Short Physical Performance Battery and all-cause mortality: Systematic review and meta-analysis 203
CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: systematic review and individual patient pooled meta-analysis 203
Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting 202
Adding a “Notch” to Cardiovascular Disease Therapeutics: A MicroRNA-Based Approach 202
Kounis-Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock 201
Predicting return to work after acute myocardial infarction: Socio-occupational factors overcome clinical conditions 200
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study 199
Fractional flow reserve: Current applications and overview of the available data 199
Ticagrelor improves endothelial function by decreasing circulating Epidermal Growth Factor (EGF) 199
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 198
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 197
Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention 197
Notch Signaling Regulates Immune Responses in Atherosclerosis 195
Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting 194
Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multicenter Italian registry (the FREAK study) 194
Exercise intervention improves quality of life in older adults after myocardial infarction: randomised clinical trial 194
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry 193
Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention 192
Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated with Second-Generation Drug-Eluting Stents 191
The Use of Multimodality Imaging for the Diagnosis of Myocardial Outpouchings and Invaginations: A Systematic Review 189
Coronary Physiology Guidance vs. Conventional Angiography for Optimization of Percutaneous Coronary Intervention: the AQVA II Trial 188
Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study 188
10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction 188
Factor XIIIA V34L and Factor XIIIB H95R Gene Polymorphisms: Effects on the Risk of Myocardial Infarction and on Survival. 187
Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease 187
Reduced rate of hospital admissions for ACS during Covid-19 outbreak in northern Italy 187
The in vitro effects of verbascoside on human platelet aggregation 186
Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients 186
Impact of COPD on Long-term Outcome After ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention 186
Transcatheter aortic-valve implantation with or without on-site cardiac surgery: The TRACS trial 185
Different clinical models of CD34 plus cells mobilization in patients with cardiovascular disease 183
Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction 183
A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) Score on 1-Year Clinical Outcomes in 6,508 Patients Enrolled in Contemporary Coronary Stent Trials 183
Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: Role of MPO specific activity in coronary artery disease 182
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy 181
Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers 180
QFR-Based Virtual PCI or Conventional Angiography to Guide PCI: The AQVA Trial 180
Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. 180
Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial 180
Radial versus femoral access in patients with acute coronary syndromes withor without ST-segment elevation 180
Totale 27.413
Salva come PNG Salva come JPEG
Categoria #
all - tutte 313.632
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.047
Totale 315.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021788 0 0 0 0 0 0 0 0 0 0 536 252
2021/20223.161 274 287 207 148 146 163 193 195 142 239 337 830
2022/20232.784 340 126 141 235 406 396 177 251 360 71 191 90
2023/20242.794 169 292 130 91 214 490 132 281 68 128 142 657
2024/202512.666 313 330 920 586 1.425 1.211 806 708 2.320 1.302 1.514 1.231
2025/202635.435 2.969 1.574 3.299 3.858 4.751 2.088 3.630 1.945 7.207 3.898 216 0
Totale 70.177